Angehrn P, Hall M J, Lloyd W J, Westmacott D
Antimicrob Agents Chemother. 1984 May;25(5):607-11. doi: 10.1128/AAC.25.5.607.
The phosphonopeptide L- norvalyl -L-1- aminoethylphosphonic acid [ Nva -Ala(P)] has been studied in combination with 12 beta-lactam antibiotics for activity against Pseudomonas aeruginosa. Nocardicin A was found to give the most potent synergistic combination with Nva -Ala(P). This interaction was widely observed in clinical isolates of P. aeruginosa in vitro and in a mouse septicemia model. Synergy was also observed in vitro and in vivo in several other species, including Proteus mirabilis, indole-positive Proteus spp., and Serratia marcescens. The interaction between Nva -Ala(P) and nocardicin A involved a strongly bacteriolytic mechanism. In addition, the individual components were complementary to one another in their action against organisms not showing synergy. These properties resulted in a broad spectrum of activity of the combination Nva -Ala(P) plus nocardicin A when used to treat experimental gram-negative bacterial infections.
已对膦肽L-正缬氨酰-L-1-氨基乙基膦酸[Nva-Ala(P)]与12种β-内酰胺类抗生素联合用于抗铜绿假单胞菌的活性进行了研究。发现诺卡菌素A与Nva-Ala(P)联合使用时具有最强的协同作用。这种相互作用在体外铜绿假单胞菌临床分离株和小鼠败血症模型中广泛观察到。在其他几种细菌中,包括奇异变形杆菌、吲哚阳性变形杆菌属和粘质沙雷氏菌,在体外和体内也观察到了协同作用。Nva-Ala(P)与诺卡菌素A之间的相互作用涉及一种强烈的溶菌机制。此外,各个组分在对抗未表现出协同作用的生物体时相互补充。当用于治疗实验性革兰氏阴性细菌感染时,这些特性导致Nva-Ala(P)加诺卡菌素A组合具有广泛的活性谱。